Levy CIMAR Associate Director and Combinatorial Treatment Core Director
Web site | Twitter | The Tuberculosis Drug Accelerator
Dr. Aldridge leads a multidisciplinary research group coupling quantitative single-cell measurements and mathematical modeling with the goal of shortening and simplifying treatment regimens against tuberculosis, which remains a threat to global health, killing ~2 million people every year. The causative agent of tuberculosis, Mycobacterium tuberculosis, is thought to infect one third of world’s population, sickening ~10 million people a year. Despite efforts to simplify treatment strategies, tuberculosis still requires months of multi-drug therapy to cure. The Aldridge Laboratory at the Tufts University School of Medicine merges engineering and molecular approaches to develop quantitative descriptions of the determinants of mycobacterial stress tolerance and virulence.
- Assistant Professor, Department of Molecular Biology and Microbiology, Tufts University School of Medicine
- Adjunct Associate Professor, Biomedical Engineering, Tufts University School of Engineering
Mycobacterial virulence, drug tolerance, computational modeling, and combination therapy